Cathelicidin LL-37 Peptide Inhibits IAPP Amyloid Self-Assembly

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Type 2 diabetes is characterized by pancreatic β-cell degeneration due to the self-assembly of islet amyloid polypeptide (IAPP) into cytotoxic oligomers and amyloid fibrils, leading to inflammation and insulin secretion insufficiency, for which current methods lack effective prevention and treatment strategies.

Innovation Solution

Upregulating cathelicidin gene expression, particularly through the administration of pharmaceutically acceptable compositions that include peptidomimetics of the cathelicidin peptide LL-37, to inhibit IAPP amyloid self-assembly and fibril formation, thereby modulating glucose metabolism and pancreatic islet function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If IAPP is secreted from β-cells to regulate glucose homeostasis, then glucose metabolism is maintained, but under T2D conditions IAPP self-assembles into cytotoxic oligomers and amyloid fibrils causing pancreatic inflammation and β-cell degeneration

Engineering Contradiction:

Improveglucose homeostasis regulationVSAvoidcytotoxic oligomers and amyloid fibrils formation

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses cathelicidin LL-37 as an intermediary substance that binds to IAPP and prevents its self-assembly into cytotoxic aggregates. LL-37 acts as a protective mediator that interferes with the harmful self-assembly process while allowing IAPP to continue its physiological function in glucose homeostasis regulation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies preliminary anti-action by administering cathelicidin LL-37 or its mimetics before IAPP can self-assemble into cytotoxic oligomers and amyloid fibrils. This preventive approach blocks the harmful aggregation process before it occurs, protecting β-cells from damage while maintaining IAPP's beneficial metabolic functions.

Inventive Principle:

Principle #9Preliminary anti-action

2Reliability

If current methods are used to treat T2D, then general diabetes management is provided, but effective prevention and treatment strategies for IAPP-induced β-cell degeneration are lacking

Engineering Contradiction:

Improvediabetes managementVSAvoideffectiveness against IAPP aggregation

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the therapeutic parameter from general diabetes management to specific targeting of IAPP aggregation. By using cathelicidin LL-37 and its peptidomimetics, the treatment specifically addresses the molecular mechanism of IAPP self-assembly, providing adaptability to the unique pathophysiology of T2D while maintaining overall diabetes management.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The upregulation of cathelicidin gene expression effectively suppresses IAPP amyloid self-assembly, reduces pancreatic β-cell damage, and improves glucose metabolism, providing a potential treatment for type 2 diabetes by inhibiting fibril formation and promoting islet function.

Implementation Method 1

Amyloid self-assembly of islet amyloid polypeptide (IAPP) is linked to pancreatic β-cell degeneration and the pathogenesis of type 2 diabetes (T2D). The 37-residue IAPP is secreted from the β-cells together with insulin, and acts in its soluble form as a neuropeptide regulator of glucose homeostasis. However, under conditions of T2D, the intrinsically disordered but highly amyloidogenic IAPP self-assembles into cytotoxic oligomers and amyloid fibrils, which mediate pancreatic inflammation and β-cell degeneration.

Methodology Applied

Scientific EffectAmyloid self-assembly inhibition:

Implementation Method 2

preventing or treating type 2 diabetes (T2D) by inhibiting the self-assembly of islet amyloid polypeptide (IAPP) into amyloid fibrils through the use of the cathelicidin peptide LL-37 or a peptidomimetic thereof

Methodology Applied

Scientific EffectPeptide binding interaction:

Data Source

PatentUS20240268768A1Method of Preventing or Treating Pancreatic Dysfunction or Diabetes by Upregulating Human Cathelicidin LL-37 to Inhibit Islet Amyloid Polypeptide (IAPP) Self-Assembly

Publication Date: 2024.08.15 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

AI summary

A method for treating type 2 diabetes (T2D) is provided. The method comprises diagnosing a subject as suffering from T2D or as being pre-diabetic; monitoring the response to glucose stimulation of at least one islet in the pancreas of the subject by quantitatively imaging glucose metabolism in vivo; establishing a target range for the response to glucose stimulation of the at least one islet; and upregulating cathelicidin gene expression in the subject until the monitored response to glucose stimulation is within the target range.